The price of Esperion Therapeutics Inc. (NASDAQ: ESPR) closed at $2.19 in the last session, down -3.95% from day before closing price of $2.28. In other words, the price has decreased by -$0.0900 from its previous closing price. On the day, 3176830 shares were traded.
Ratios:
We take a closer look at ESPR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.87 and its Current Ratio is at 1.29.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 20 ’23 when Warren Eric sold 742 shares for $1.25 per share. The transaction valued at 924 led to the insider holds 68,318 shares of the business.
Warren Eric sold 243 shares of ESPR for $344 on Aug 18 ’23. The Chief Commercial Officer now owns 69,060 shares after completing the transaction at $1.41 per share. On Jul 19 ’23, another insider, Warren Eric, who serves as the Chief Commercial Officer of the company, sold 106 shares for $1.58 each. As a result, the insider received 168 and left with 69,303 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 405.27M and an Enterprise Value of 589.19M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.21. Its current Enterprise Value per Revenue stands at 5.06 whereas that against EBITDA is -3.93.
Stock Price History:
Over the past 52 weeks, ESPR has reached a high of $5.18, while it has fallen to a 52-week low of $0.70. The 50-Day Moving Average of the stock is 2.5062, while the 200-Day Moving Average is calculated to be 1.6336.
Shares Statistics:
According to the various share statistics, ESPR traded on average about 6.38M shares per day over the past 3-months and 4.41M shares per day over the past 10 days. A total of 170.42M shares are outstanding, with a floating share count of 169.51M. Insiders hold about 0.53% of the company’s shares, while institutions hold 48.10% stake in the company. Shares short for ESPR as of Feb 15, 2024 were 18.57M with a Short Ratio of 2.91, compared to 20.2M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.03% and a Short% of Float of 11.21%.
Earnings Estimates
The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.46 and a low estimate of -$0.31, while EPS last year was -$0.79. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.15 and low estimates of -$0.25.
Analysts are recommending an EPS of between $0.04 and -$1 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is $0.2, with 5 analysts recommending between $1.49 and -$0.34.
Revenue Estimates
According to 7 analysts, the current quarter’s revenue is expected to be $76.86M. It ranges from a high estimate of $141.69M to a low estimate of $28.9M. As of the current estimate, Esperion Therapeutics Inc.’s year-ago sales were $24.33M, an estimated increase of 215.90% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $41.91M, an increase of 62.50% less than the figure of $215.90% in the same quarter last year. There is a high estimate of $48.35M for the next quarter, whereas the lowest estimate is $38M.
A total of 7 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $337.5M, while the lowest revenue estimate was $174M, resulting in an average revenue estimate of $257.54M. In the same quarter a year ago, actual revenue was $116.33M, up 121.40% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $398.87M in the next fiscal year. The high estimate is $710.2M and the low estimate is $272.94M. The average revenue growth estimate for next year is up 54.90% from the average revenue estimate for this year.
